Despite Price Tags, Economics Driving M&A Will Endure In ’08, Biotech Investors Say
This article was originally published in The Pink Sheet Daily
Recession indicators are giving health care investors the jitters but fund managers at BIO CEO & Investor Conference remain confident on biotech.
You may also be interested in...
Despite Strategic Review, Biogen Idec To Remain Independent
The biotech has not received “any definitive offers.”
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.